BioSpace News Archive

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA ® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED).

Alzamend plans two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer’s disease.

Allurion , a company dedicated to ending obesity, today announced a pilot collaboration agreement with Medtronic, a global leader in healthcare technology, to expand access to Allurion’s AI-powered weight loss program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) regions.

Lunaphore Technologies SA , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Nuo Therapeutics, Inc., a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage, the nation’s leading wound care consulting firm has added the Aurix® System to its formulary.

Kymera Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML).

Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 system to include all people who use basal insulin as part of their diabetes management.

Tvardi Therapeutics, Inc. today announced that the first patients have been dosed in each arm of its ongoing REVERT LIVER CANCER trial.

Beta Bionics, Inc. - a medical technology company focused on diabetes - announces FDA 510(k) clearance for compatibility with the Fiasp Pumpcart (insulin aspart) prefilled insulin cartridge.

Propanc Biopharma, Inc. today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.